Federal Circuit Orders District Court to Consider Extrinsic Evidence in Claim Construction -
In Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., Appeal No. 22-1889, the Federal Circuit held that where a...more
12/5/2023
/ Article III ,
Claim Construction ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Mylan Pharmaceuticals ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Purdue Pharma ,
Standing
Venue and Pleading Infringement in Hatch-Waxman Litigation Turn on Location and Identity of ANDA Filer -
In Celgene Corp. v. Mylan Pharm. et al., Appeal No. 21-1154, the Federal Circuit held that in Hatch-Waxman...more
12/9/2021
/ Abbreviated New Drug Application (ANDA) ,
Apple ,
Article III ,
Biogen Idec ,
Dr. Reddy’s Labs. ,
Generic Drugs ,
Hatch-Waxman ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Mylan Pharmaceuticals ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Qualcomm ,
Standing ,
Written Descriptions
Evidence Supports Prior Art’s Public Accessibility but Not the Board’s Adoption of an Unpresented Theory of Anticipation -
In M & K Holdings, Inc. v. Samsung Electronics Co.,Ltd., Appeal No. 20-1160, the Federal Circuit...more
3/26/2021
/ Abstract Ideas ,
Anticipation ,
Article III ,
Covered Business Method Proceedings ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Printed Publications ,
Prior Art ,
Section 102
PTAB May Invalidate Claims on Reconsideration Based on Grounds Raised in the Institution Decision that Were Not Originally Instituted -
In AC Technologies S.A., V. Amazon.Com, Inc., Blizzard Entertainment, Inc., Appeal No....more
3/14/2019
/ Abbreviated New Drug Application (ANDA) ,
Amazon ,
Anticipation ,
Appeals ,
Article III ,
Due Process ,
Final Written Decisions ,
Generic Drugs ,
Hatch-Waxman ,
Hewlett-Packard ,
Inter Partes Review (IPR) Proceeding ,
Motivation to Combine ,
Mylan Pharmaceuticals ,
Obviousness ,
Orange Book ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Petition For Rehearing ,
Pharmaceutical Patents ,
Reaffirmation ,
Right To Appeal ,
Section 103 ,
Standing
A Complaint Identifying Infringing Products and the Patents Allegedly Infringed, Accompanied by Statements that the Products Meet All Elements of at Least One Claim of the Asserted Patents, May be Sufficient to Meet the...more
7/12/2018
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Article III ,
Contract Termination ,
Declaratory Judgments ,
Federal Rule 12(b)(6) ,
Final Written Decisions ,
Foreign Corporations ,
FRCP 12(b)(2) ,
FRCP 12(b)(3) ,
Improper Venue ,
International Litigation ,
Motion to Dismiss ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Personal Jurisdiction ,
Post-Grant Review ,
Principal Place of Business ,
Specific Jurisdiction ,
Standing ,
Twombly/Iqbal Pleading Standard ,
Venue ,
Writ of Mandamus
IPR Appellants Must Satisfy Article III Standing -
In Personal Audio, LLC v. Electronic Frontier Foundation, Appeal No. 2016-1123, the Federal Circuit held that standing for an appeal to a federal court is based on the...more
10/24/2017
/ Abstract Ideas ,
Appeals ,
Article III ,
Computer-Related Inventions ,
Inter Partes Review (IPR) Proceeding ,
Lost Profits ,
Patent Infringement ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Prior Art ,
Standing ,
USPTO
The Federal Circuit Will Review Appeals from Inter Partes Review Proceedings Under the “Substantial Evidence” Standard -
In Merck & Cie v. Gnosis S.p.A., Appeal No. 2014-1779, the Federal Circuit affirmed a PTAB IPR...more
2/1/2016
/ Apple ,
Article III ,
Burden of Proof ,
Cisco ,
Covered Business Method Proceedings ,
Hewlett-Packard ,
Inter Partes Review (IPR) Proceeding ,
Merck ,
Motion to Amend ,
Myriad-Mayo ,
Obviousness ,
Patent Invalidity ,
Patent Litigation ,
Patent Royalties ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Sequenom ,
Seventh Amendment ,
Standard Essential Patents ,
Substantial Evidence Standard ,
USPTO